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The cadherin–catenin cell adhesion complex mediates homotypic
cell–cell adhesion and is known to play a fundamental role in
embryonic development, morphogenesis and maintenance of the
epithelial phenotype (Takeichi, 1995). Fluctuations in cell–cell
adhesion are thought to be key events in the progression from
localized malignancy to metastatic disease and several in-vitro
studies have confirmed that E-cadherin acts as a tumour
suppressor protein (Vleminckx et al, 1991; Kinsella et al, 1994).
Reduced E-cadherin expression has been reported in a variety of
human tumours and in many cases these changes correlate with
advanced disease (Shiozaki et al, 1996). However, the evidence in
relation to colorectal cancer is less convincing. Some colorectal
tumours expressing E-cadherin metastasize and some liver metas-
tases strongly express E-cadherin (Kinsella et al, 1993; Gagliardi
et al, 1995). In tumours with normal expression of E-cadherin,
perturbations of the cadherin cell adhesion system may be due
to abnormal expression or function of the associated catenins
(Takeichi, 1993).
Functional cadherin-dependent cell adhesion requires the
formation of complexes between E-cadherin and the cytosolic
proteins a-catenin, b-catenin and plakoglobin (g-catenin) (Ozawa
and Kemler, 1992). b-Catenin and plakoglobin share amino acid
homology and bind, in a mutually exclusive fashion, to the
cytoplasmic domain of E-cadherin (Jou et al, 1995). b-Catenin
competes with plakoglobin for binding to a-catenin which, in turn,
is linked to the actin cytoskeleton (Knudsen et al, 1995).
Recently it has become evident that there are cadherin-indepen-
dent, as well as cadherin-bound, catenin pools and that these two
pools may serve different functions (Hinck et al, 1994; Jou et al,
1995). In colorectal cancer cell lines, elevated cytoplasmic levels
of b-catenin are down-regulated by the product of the tumour
suppressor gene APC, which has been shown to function in
concert with glycogen synthase kinase-3b (GSK-3b) to regulate
levels of uncomplexed b-catenin (Rubinfeld et al, 1996). This
regulatory mechanism is also known to be part of a signalling
pathway for b-catenin which controls cell growth and proliferation
in vertebrate embryos (Gumbiner, 1995). Despite numerous
studies documenting expression of the individual components of
the cadherin–catenin cell adhesion complex in various tumour
types, the role of the complex in tumourigenesis is still not fully
understood. In colorectal cancer, the possible dual role of b-
catenin in cell adhesion and in growth signalling events, and the
relationship of these functions to patient outcome, remains to be
clarified.
The aim of this study was to examine the expression of the
components of the cadherin–catenin cell adhesion complex in
colorectal cancer and attempt to correlate these findings with
standard clinico-pathological parameters and patient survival.
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Summary Both cell adhesion and cell signalling events are mediated by components of the cadherin–catenin complex. Loss of expression of
the components of this complex have been shown to correlate with invasive behaviour in many tumour types although their exact role in
colorectal cancer remains unclear. Immunohistochemical analysis of the expression of components of the cadherin–catenin complex in
colorectal cancers from 60 patients was undertaken. Loss of memberanous expression of E-cadherin, a-catenin and b-catenin was
demonstrated in 52%, 85% and 40% of tumours respectively. Focal nuclear expression of b-catenin (< 75% of cells per section), usually
associated with cytoplasmic expression, was clearly demonstrated in 19 (32%) tumours while widespread nuclear expression (> 75% of
tumour cells per section) was seen in 11 (18%) tumours. Loss of membranous a-catenin expression significantly correlated with tumour de-
differentiation (P = 0.009). There was a trend towards an association between advanced tumour stage and loss of membranous expression
of a-catenin or b-catenin, although these associations were not statistically significant. Univariate analysis revealed that advanced Dukes’
stage, tumour de-differentiation, loss of membranous b-catenin expression, cytoplasmic b-catenin expression and widespread nuclear
expression of b-catenin all correlated with short survival following apparently curative resection of the primary tumour. However, only Dukes’
stage (P = 0.002), tumour grade (P = 0.02) and widespread nuclear expression of b-catenin (P = 0.002) were independent predictors of short
survival. Disturbed growth signalling events in colorectal tumours are thought to result in nuclear accumulation of b-catenin. Consequently,
tumours with widespread nuclear expression of b-catenin are likely to have severely abnormal growth characteristics, and which therefore
might be predictive of short survival in these patients.
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MATERIALS AND METHODS
Tumour specimens
Tumour samples were obtained from 60 patients who underwent
apparently curative resection of a primary colorectal carcinoma at
the Royal Liverpool University Hospital between 1989 and 1994.
The present series includes 44 patients whose colorectal tumours
were previously examined for E-cadherin expression (Kinsella et
al, 1993). Only one patient in the series had familial adenomatous
polyposis and no patient received chemotherapy or radiotherapy
prior to undergoing resection of the primary tumour. Tumour spec-
imens and samples of normal colonic epithelium were collected at
the time of resection and were snap-frozen and stored in liquid
nitrogen until required. Clinico-pathological information and
survival data were obtained from the hospital records, from death
certificates or by contact with the local family practitioner.
Immunohistochemistry
The avidin–biotin indirect immunoperoxidase method was used for
immunohistochemical staining, as described previously (Andrews
et al, 1997). Briefly, frozen sections (6 mM) of tumour samples were
cut and fixed in ice-cold acetone followed by treatment with 1.2%
hydrogen peroxide in methanol for 10 min to block endogenous
peroxidase activity. The sections were incubated with either anti-E-
cadherin (HECD-1) monoclonal IgG (R & D Systems Europe,
Abingdon, UK) diluted 1:200 in Tris-buffered saline pH 7.6 (TBS),
or anti-b-catenin monoclonal IgG (Transduction Laboratories,
Lexington, KY, USA) diluted 1:100 in TBS, or anti-a-catenin
monoclonal IgG (Transduction Laboratories, Lexington, KY, USA)
diluted 1:20 in TBS. The sections were then thoroughly washed
with TBS followed by addition of a biotinylated anti-mouse IgG
(Amersham Life Sciences, UK). After incubation with ABC
reagent (Dako, UK) the signal was finally developed with
diaminobenzidine containing 0.01% hydrogen peroxide. Normal
colonic epithelium was used as an internal positive control; nega-
tive controls consisted of adjacent sections in which the primary
antibody was replaced by either non-specific mouse IgG or TBS.
Table 1 Membranous expression of the cadherin–catenin complex (n = 60)
Loss of membranous Strong membranous
expression (%) expression (%)
E-cadherin 31 (52) 29 (48)
a-catenin 51 (85) 9 (15)
b-catenin 24 (40) 36 (60)
AB
CD
Figure 1 (A) Cytoplasmic expression of a-catenin in a colonic carcinoma with normal colon internal control above (6003). (B) Strong membranous expression
of b-catenin in normal colon (6003). (C) Weak membranous expression of b-catenin in a colonic carcinoma (6003). (D) Cytoplasmic, nuclear, and weak
membranous expression of b-catenin in a colonic carcinoma (6003)1048 TJ Hugh et al
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Scoring
Sections were examined under light microscopy and the predomi-
nant pattern of immunostaining within each section was used to
determine the final score. Tumours displaying well-localized
membranous staining similar to that seen in normal colorectal
mucosa were scored as (2+); those displaying reduced membra-
nous immunoreactivity were scored as (1+); tumours with no
immunolabelling were scored as (0). Tumours were additionally
subdivided into either cytoplasmic (+c) or nuclear (+n) localiza-
tion. Nuclear expression of tumour cells was arbitrarily scored as
either widespread (> 75% of cells per section), focal (< 75% of
cells per section) or absent (no nuclear staining). All tumours were
re-assessed for differentiation status by a single pathologist inde-
pendent of the original pathology report.
Statistical analysis
Kendall’s Tau-b correlation was used to measure relationships
between the expression of the components of the cadherin–catenin
complex. The c2 test, or Fisher’s exact test where appropriate, was
used to compare antigen expression with standard clinico-patholog-
ical parameters. Overall patient survival rates were calculated by
the Kaplan–Meier method and the log-rank test was used for differ-
ences between survival curves. A P-value of < 0.05 was accepted as
statistically significant. Variables were subjected to univariate
analysis and after confirmation that the log–log plots did not
deviate from the proportional hazards assumption, significant vari-
ables were subjected to multivariate analysis using the Cox regres-
sion model. The SPSS for Windows statistical package (Version
6.1.2, 2nd May, 1995) was used for all statistical analyses.
RESULTS
Normal colorectal tissue
All normal mucosal specimens showed distinct, evenly distributed
immunostaining for E-cadherin, a-catenin (Figure 1A) and b-
catenin (Figure 1B) along the intercellular borders, but not at the
cell surface facing the basement membrane. All three antigens
displayed some basal cytoplasmic expression in colorectal cells
located towards the luminal surface of the crypts. There was no
detectable nuclear staining of either E-cadherin or the catenins in
any section of normal colonic mucosa.
Tumour tissue
Only six (10%) tumours displayed normal membranous expres-
sion (2+) of all three components of the cadherin–catenin
complex, while five (8%) tumours displayed reduced or absent
expression (1+ or 0) of all components of the complex. Tables 1
and 2 provide a summary of the immunohistochemical findings.
Loss of expression of E-cadherin was manifest as either dis-
continuous, weak immunolabelling at the intercellular borders or
localized expression at the apicolateral cell junctions only. In some
tumours faint cytoplasmic expression of E-cadherin was scattered
throughout the cell. Overall, expression of a-catenin (Figure 1A)
in tumours was less marked than either E-cadherin or b-catenin;
in 25 (42%, 95% confidence interval (CI) 30–54) tumours there
was complete absence of a-catenin expression. With regard to
b-catenin, only 15 (25%, 95% CI 19–31) tumours displayed purely
membranous expression, equivalent to that seen in normal colon;
in the majority of tumours subcellular b-catenin staining was
observed. Overall, there was good correlation between loss of
membranous expression of b-catenin (Figure 1C) and widespread
nuclear staining of b-catenin (Figure 1D) (Fisher’s exact test,
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Figure 2 Kaplan–Meier survival curve showing a statistically significant
survival advantage in patients with tumours displaying focal or absent
nuclear expression of b-catenin (n = 49, —) compared with those displaying
widespread nuclear expression of b-catenin (n = 11, - - -) (log-rank test,
c2
1 = 9.74, P = 0.002)
Table 2 Non-membranous expression of the cadherin–catenin complex
(n = 60)
n = 60 Non-membranous distribution of the
cadherin–catenin complex (%)
E-cadherin 5   (9) Faint cytoplasmic staining
a-catenin 25 (42) Cytoplasmic staining
b-catenin 45 (75) Diffuse cytoplasmic staining
19 (32) Focal nuclear staining (< 75% of the section)
11 (18) Widespread nuclear staining (> 75% of the section)
Table 3 Relationship between loss of membranous expression of the
cadherin–catenin complex (1 + or 0) and tumour grade
Tumour grade Total E-cadherin (%) a-catenin (%) b-catenin (%)
1 + or 0 1 + or 0 1+
Well 8 3 (38) 4 (50) 1 (13)
Moderate 46 24 (52) 41 (89) 20 (43)
Poor 6 4 (67) 6 (100) 3 (50)
P-value 0.55 0.009 0.22
Table 4 Relationship between loss of membranous expression of the
cadherin–catenin complex (1+ or 0) and Dukes’ stage
Dukes’ stage Total E-cadherin (%) a-catenin (%) b-catenin (%)
1+ or 0 1+ or 0 1+
A 6 4 (67) 4 (67) 0 (0)
B 35 14 (40) 28 (80) 14 (40)
C 19 13 (68) 19 (100) 10 (53)
P-value 0.10 0.06 0.07Cadherin–catenin expression in colorectal cancer 1049
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two-tailed, P = 0.04). However, this was not an absolute finding
and within some sections tumour cells displayed both nuclear and
strong membranous expression of b-catenin.
There was no apparent statistical relationship between any form of
b-catenin expression and either E-cadherin or a-catenin expression.
However, there was a statistically significant relationship between
E-cadherin and a-catenin expression (Kendall’s Tau-b, R = 0.25,
P = 0.05), with tumours displaying loss of membranous E-cadherin
expression often also displaying loss of a-catenin expression.
Relationship with clinico-pathological parameters
Poorly differentiated tumours displayed greater loss of a-catenin
expression when compared with moderately or well-differentiated
tumours (c2
2 = 9.4, P = 0.009). Although there was a trend towards
greater loss of membranous E-cadherin or b-catenin expression in
less well-differentiated tumours, these findings were not statistically
significant (Table 3). Tumours with reduced or absent membranous
expression of a-catenin or b-catenin were more likely to develop
regional lymph node metastases, although these associations did not
reach statistical significance (Table 4). Furthermore, there was no
apparent association between expression of the cadherin–catenin
complex and patient gender or site of the primary tumour.
Survival analysis
The median survival of the patients in this series from the time of
primary tumour resection was 1720 days, with a 5-year actuarial
survival of 46%. One patient died of an acute myocardial infarc-
tion immediately post-operatively (1.6% 30-day mortality) and
two other patients died of non-cancer-related causes during subse-
quent follow-up. However, all three patients were known to be
disease-free at the time of death. Two other patients who were lost
to follow-up at 5 and 7 months post-operatively were also disease-
free at the time of census.
As expected, both Dukes’ staging and tumour grade were
important prognostic factors. When subjected to univariate
analysis, advanced Dukes’ stage (log-rank test, c2
2 = 19.75,
P = 0.0001) and tumour de-differentiation (log-rank test,
c2
2 = 10.03, P = 0.007) correlated with short survival and death
from metastatic colorectal cancer. In addition, loss of membranous
expression of b-catenin (log-rank test, c2
1 = 4.52, P = 0.03),
cytoplasmic expression of b-catenin (log-rank test, c2
1 = 3.81,
P = 0.05), and widespread nuclear expression of b-catenin (log-
rank test, c2
1 = 9.74, P = 0.0018, Figure 2) were also statistically
associated with short survival and death from metastatic colorectal
cancer. In contrast, there was no apparent association between
long-term survival and either sex of the patient, site of the primary
tumour, expression of E-cadherin or expression of a-catenin.
However, when the relevant significant variables were
subjected to multivariate analysis only Dukes’ staging (P = 0.002),
tumour grade (P = 0.02) and widespread nuclear expression of
b-catenin (P = 0.002) were independent predictors of short
survival. Patients with tumours displaying widespread nuclear
staining of b-catenin (> 75% of tumour cells) had an overall 5-year
survival of only 18% compared with 63% for patients whose
tumours had focal or absent nuclear staining of b-catenin.
DISCUSSION
In the present study, a-catenin expression in colorectal tumours was
reduced or lost more frequently than either E-cadherin or b-catenin,
and this reduction in expression correlated significantly with deteri-
orating tumour grade. Similar findings have been reported previ-
ously in several other tumour types (Kadowaki et al, 1994; Matsui et
al, 1994; Takayama et al, 1994). The mechanisms resulting in loss of
a-catenin expression in tumours are not fully understood. However,
homozygous deletion of the a-catenin gene, resulting in loss of a-
catenin expression, has been demonstrated in cell lines from both
lung and prostatic carcinomas (Shimoyama et al, 1992; Morton et al,
1993). Furthermore, Yasui et al (1995) have reported complete dele-
tion of the a-catenin gene in one of 10 gastric carcinomas examined.
It has also been suggested that loss of a-catenin expression in
tumours may relate to a post-transcriptional mechanism which is
regulated by E-cadherin and which controls a-catenin protein
expression (Nagafuchi et al, 1991). Dependence on E-cadherin for
transcriptional regulation, as well as dependence on b-catenin for
binding and incorporation into the cadherin–catenin complex may
provide an explanation for the relatively early and frequent loss of
a-catenin expression seen in many tumours. Consequently, loss of
a-catenin might be the most sensitive indicator of cadherin–catenin
complex dysfunction.
In contrast to previous reports, the present study has, for the first
time, documented the relationship between expression of all three
components of the cadherin–catenin complex in colorectal tumours
and long-term survival. Others have reported an apparent associa-
tion between loss of E-cadherin expression in colorectal tumours
and advanced tumour stage and decreased survival (Dorudi et al,
1995); however, a similar relationship was not found in either an
earlier study (Kinsella et al, 1993) or in the present one.
Loss of membranous b-catenin expression has been docu-
mented in a variety of tumour types, including colorectal cancer
(Hashizume et al, 1996; Takayama et al, 1996; Hao et al, 1997a;
Hiscox and Jiang, 1997; Jawhari et al, 1997). In our study, 40% of
colorectal tumours displayed loss of membranous b-catenin
expression and these changes correlated significantly with short
survival of patients (P = 0.033); a similar association has been
previously reported in gastric and oesophageal adenocarcinomas
(Jawhari et al, 1997; Krishnadath et al, 1997).
Nuclear expression of b-catenin in familial and sporadic
colorectal tumours has recently been reported (Inomata et al, 1996;
Takayama et al, 1996; Hao et al, 1997b; Valizadeh et al, 1997).
Prior to this, subcellular localization of b-catenin was identified in
mesodermal cells of vertebrate embryos during specific growth
signalling events (Miller and Moon, 1996). Subsequently,
Valizadeh and co-workers clearly demonstrated that early
dysplastic colonic polyps, but not inflammatory or hyperplastic
polyps, may display both cytoplasmic and nuclear localization of
b-catenin (Valizadeh et al, 1997), suggesting that these changes
are specific and early events in the development of colorectal
cancer. The present study has extended these observations and
demonstrates that up to 75% of sporadic colorectal cancers may
display either cytoplasmic expression or nuclear localization of
b-catenin. Furthermore, varying degrees of b-catenin nuclear
expression are often found, with some tumours displaying focal
staining only while others demonstrate more widespread staining.
Recent experimental and clinical evidence has demonstrated
that cytoplasmic over-expression and nuclear translocation of b-
catenin in colorectal tumour cells is usually a result of mutations in
either the APC or b-catenin genes (Morin et al, 1997; Rubinfeld et
al, 1997; Iwao et al, 1998). Furthermore, unregulated subcellular
b-catenin protein has been shown to activate gene expression by
complex formation with a family of nuclear transcription factors(Behrens et al, 1996; Molenaar et al, 1996; Korinek et al, 1997).
The finding of an association between widespread nuclear expres-
sion of b-catenin in tumour cells and short survival in patients with
colorectal cancer (Figure 2) has not been reported previously.
Unfortunately, in our study clinical information regarding sites of
first recurrence of colorectal cancer was not available in all
patients and therefore we cannot comment on whether widespread
nuclear expression of b-catenin is more likely to be associated
with either local, haematogenous or lymphatic metastases.
Failure to demonstrate loss of membranous expression of b-
catenin as an independent predictor of survival conflicts with the
findings of a recent study of patients with gastric cancer (Jawhari
et al, 1997). Although the reasons for these differences are unclear,
it is interesting to note from work done in our own laboratory
(unpublished data) and by others (Jawhari et al, 1997), that nuclear
expression of b-catenin is uncommon in gastric cancer compared
with colorectal cancer, possibly because of less frequent APC
mutations in gastric tumours.
In the present series of colorectal tumours, good correlation
between loss of membranous b-catenin expression and widespread
nuclear localization of b-catenin (P = 0.04) was demonstrated.
Similar reciprocity between membranous and nuclear staining of
b-catenin has been demonstrated in colorectal adenomas and
carcinomas recently (Hao et al, 1997b). However, in our study this
relationship was not absolute and some tumours contained cells
displaying both nuclear and strong membranous expression of
b-catenin. Although there is evidence that the cadherin-binding
and signalling activities of b-catenin may reside in separate
regions of the protein (Gumbiner, 1995), the exact relationship
between cadherin-bound b-catenin mediating cell adhesion and
non-cadherin-bound b-catenin functioning as part of a growth
signalling pathway remains unclear. It is possible the final tumour
phenotype in colorectal cancer may depend on the relative func-
tional activity of each of these regions.
In conclusion, this study demonstrates that loss of membranous
expression of E-cadherin or b-catenin in colorectal tumours may
not add prognostic information to standard clinico-pathological
parameters. While a-catenin expression in colorectal cancers may
reflect tumour differentiation status, our results suggest that it does
not predict long-term patient outcome. In contrast, widespread
nuclear expression of b-catenin in colorectal tumours, which
possibly reflects unregulated growth signalling events, may distin-
guish tumours which behave aggressively. This preliminary report
of a relationship between widespread nuclear expression of
b-catenin and short survival in colorectal cancer needs to be
confirmed in larger studies. It will be necessary to clarify the
exact relationship between cell adhesion and cell signalling pools
of  b-catenin in colorectal cancer in order to understand the
mechanisms underlying this finding.
ACKNOWLEDGEMENTS
This work was funded by grants from the Royal Australasian
College of Surgeons (TJH) and the North West Cancer Research
Fund (ARK)
REFERENCES
Andrews NA, Jones AS, Helliwell TR and Kinsella AR (1997) Expression of the
E-cadherin–catenin cell adhesion complex in primary squamous cell cancer of
the head and neck and their nodal metastases. Br J Cancer 75: 1474–1480
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier
W (1996) Functional interaction of b-catenin with the transcription factor
LEF-1. Nature 382: 638–642
Dorudi S, Hanby AM, Poulsom R, Northover J and Hart IR (1995) Level of
expression of E-cadherin mRNA in colorectal cancer correlates with clinical
outcome. Br J Cancer 71: 614–616
Gagliardi G, Kandemir O, Liu D, Guida M, Benvestito S, Ruers TGM, Benjamin IS,
Northover JMA, Stamp GWH, Talbot IC and Pignatelli M (1995) Changes in
E-cadherin immunoreactivity in the adenoma–carcinoma sequence of the large
bowel. Virchows Arch 426: 149–154
Gumbiner BM (1995) Signal transduction by b-catenin. Curr Opin Cell Biol 7:
634–640
Hao XP, Palazzo JP, Ilyas M, Tomlinson IPM and Talbot IC (1997a) Reduced
expression of molecules of the cadherin/complex in the transition from
colorectal adenoma to carcinoma. Anticancer Res 17: 2241–2247
Hao XP, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC (1997b ) Reciprocity between
membranous and nuclear expression of beta-catenin in colorectal tumours.
Virchows Arch 431: 167–172
Hashizume R, Koizumi H, Ihara A, Ohta T and Uchikoshi T (1996) Expression of
beta-catenin in normal tissue and breast carcinoma: a comparative study with
epithelial cadherin and alpha-catenin. Histopathology 29: 139–146
Hinck L, Nathke IS, Papkoff J and Nelson WJ (1994) Dynamics of cadherin/catenin
complex formation – novel protein interactions and pathways of complex
assembly. J Cell Biol 125, 1327–1340
Hiscox S and Jiang WG (1997). Expression of E-cadherin, a, b, and g-catenin in
human colorectal cancer. Anticancer Res 17: 1349–1354
Inomata M, Ochiai A, Akimoto S, Kitano S and Hirohashi S (1996) Alteration of b-
catenin expression in colonic epithelial cells of familial adenomatous polyposis
patients. Cancer Res 56: 2213–2217
Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguru S,
Nakamura Y and Miyoshi Y (1998) Acivation of b-catenin gene by interstitial
deletions involving exon 3 in primary colorectal carcinomas without
adenomatous polyposis coli mutations. Cancer Res 58: 1021–1026
Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M and Farthing JG (1997)
Abnormal immunoreactivity of the E-cadherin–catenin complex in gastric
carcinoma: relationship with patient survival. Gastroenterology 112: 46–54
Jou TS, Stewart DB, Stappert J, Nelson WJ and Marrs JA (1995) Genetic and
biochemical dissection of protein linkages in the cadherin–catenin complex.
Proc Natl Acad Sci USA 92: 5067–5071
Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki Y, Iihara K, Matsui S,
Iwazawa T, Nagafuchi A, Tsukita S and Mori T (1994) E-cadherin and
a-catenin expression in human esophageal cancer. Cancer Res 54: 291–296
Kinsella AR, Green B, Lepts GC, Hill CL, Bowie G and Taylor BA (1993) The role
of the cell–cell adhesion molecule E-cadherin in large bowel tumour cell
invasion and metastasis. Br J Cancer 67: 904–909
Kinsella AR, Lepts GC, Hill CL and Jones M (1994) Reduced E-cadherin expression
correlates with increased invasiveness in colorectal carcinoma cell lines. Clin
Exp Metastatasis 12: 335–342
Knudsen KA, Soler AP, Johnson KR and Wheelock MJ (1995) Interaction of alpha-
actinin with the cadherin–catenin cell–cell adhesion complex via a-catenin.
J Cell Biol 130: 67–77
Korinek V, Barker N, Morin PJ, Van Wichen D, de Weger R, Kinzler KW,
Vogelstein B and Clevers H (1997) Constitutive transcriptional activation by a
b-catenin–Tcf complex in APC2/2 colon carcinoma. Science 275: 1784–1787
Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WCJ, Kremers ED, Dinjens
WNM and Bosman FT (1997) Reduced expression of the cadherin–catenin
complex in oesophageal adenocarcinoma correlates with poor prognosis
J Pathol 182: 331–338
Matsui S, Shiozaki H, Inoue M, Tamura S, Doki Y, Kadowaki T, Iwazawa T,
Shimaya K, Nagafuchi A, Tsukita S and Mori T (1994) Immunohistochemical
evaluation of a-catenin expression in human gastric cancer. Virchows Arch
424: 375–381
Miller JR and Moon RT (1996) Signal transduction through b-catenin and
specification of cell fate during embryogenesis. Genes Dev 10: 2527–2539
Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S,
Korinek V, Roose J, Destree O and Clevers H (1996) XTcf-3 transcription
factor mediates b-catenin-induced axis formation in Xenopus embryos. Cell
86: 391–399
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler
KW (1997) Activation of b-catenin-Tcf signalling in colon cancer by mutations
in b-catenin or APC. Science 275: 1787–1790.
Morton RA, Ewing CM, Nagafuchi A, Tsukita S and Isaacs WB (1993) Reduction of
E-cadherin levels and deletion of the alpha-catenin gene in human prostate
cancer cells. Cancer Res 53: 3585–3590
1050 TJ Hugh et al
British Journal of Cancer (1999) 80(7), 1046–1051 © 1999 Cancer Research Campaign Cadherin–catenin expression in colorectal cancer 1051
British Journal of Cancer (1999) 80(7), 1046–1051 © 1999 Cancer Research Campaign 
Nagafuchi A, Takeichi M and Tsukita S (1991) The 102 kd cadherin-associated
protein: similarity to vinculin and post-transcriptional regulation of expression.
Cell 65: 849–857
Ozawa M and Kemler R (1992) Molecular organization of the uvomorulin–catenin
complex. J Cell Biol 116: 989–996.
Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S and Polakis P (1996) Binding
of GSK3b to the APC-b-catenin complex and regulation of complex assembly.
Science 272: 1023–1026
Rubinfeld B, Albert I, Porfiri E, Munemitsu S and Polakis P (1997) Loss of beta-
catenin regulation by the APC tumor suppressor protein correlates with loss of
structure due to common somatic mutations of the gene. Cancer Res 57:
4624–4630
Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S and
Hirohashi S (1992) Cadherin dysfunction in a human cancer cell line – possible
involvement of loss of alpha-catenin expression in reduced cell–cell
adhesiveness. Cancer Res 52: 5770–5774
Shiozaki H, Oka H, Inoue M, Tamura S and Monden M (1996) E-cadherin mediated
adhesion system in cancer cells. Cancer 77: 1605–1613
Takayama T, Shiozaki H, Inoue M, Tamura S, Oka H, Kadowaki T, Takatsuka Y,
Nagafuchi A, Tsukita S and Mori T (1994) Expression of E-cadherin and a-
catenin molecules in human breast cancer tissues and association with
clinicopathological features. Int J Oncol 5: 775–780
Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M,
Monden T, Ito F and Monden M (1996) b-Catenin expression in human cancer.
Am J Pathol 148: 39–46
Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis.
Curr Opin Cell Biol 5: 806–811
Takeichi M (1995) Morphogenic roles of classic cadherins. Curr Opin Cell Biol 7:
619–627
Valizadeh A, Karayiannakis AJ, El-Hariry I, Kmiot W and Pignatelli M (1997)
Expression of E-cadherin-associated molecules (a-, b-, g-catenin and p120) in
colorectal polyps. Am J Pathol 150: 1977–1984
Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and van-Roy F (1991) Genetic
manipulation of E-cadherin expression by epithelial tumour cells reveals an
invasion suppressor role. Cell 66: 107–119
Yasui W, Kuniyasu H, Akama Y, Kitahara K, Nagafuchi A, Ishihara S, Tsukita S and
Tahara E (1995) Expression of E-cadherin, a-catenins and b-catenins in human
gastric carcinomas – correlation with histology and tumour progression. Oncol
Rep 2: 111–117